Growth hormone tested to build muscle, reduce fat in rare genetic disorder
NCT ID NCT04697381
Summary
This study tested whether a growth hormone medicine (somatropin) is safe and can improve body composition in Japanese children and adults with Prader-Willi Syndrome (PWS). The 33 participants, who were either new to treatment or had been on it, were monitored for 12 months to see changes in muscle mass and body fat. The main goal was to see if the treatment helps build lean body mass, which is a key challenge in managing PWS.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRADER-WILLI SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dokkyo Medical University Saitama Medical Center
Koshigaya, Saitama, 343-8555, Japan
-
Hamamatsu University Hospital
Hamamatsu, Shizuoka, 431-3192, Japan
-
Kanagawa Children's Medical Center
Yokohama, Kanagawa, 232-8555, Japan
-
National Center for Child Health and Development
Setagaya-ku, Tokyo, 157-8535, Japan
-
Osaka Women's and Children's Hospital
Izumi, Osaka, 594-1101, Japan
Conditions
Explore the condition pages connected to this study.